Press Releases

INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis at COSM 2023

Posted on April 27, 2023

European Committee for Orphan Medicinal Products Provides Positive Opinion on INOVIO’s Application for Orphan Drug Designation for INO-3107

Posted on April 26, 2023

Data from Phase 1b trial with INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) presented at ECCMID 2023

Posted on April 17, 2023

INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) at ECCMID 2023

Posted on April 12, 2023

INOVIO Reports Inducement Grant Under Inducement Plan

Posted on April 3, 2023

INOVIO to Present at the Oppenheimer 33rd Annual Healthcare Conference

Posted on March 3, 2023

INOVIO Reports Fourth Quarter and Full Year 2022 Financial Results and Clinical Highlights

Posted on March 1, 2023

INOVIO Announces Positive Preliminary Results from Second Cohort of Phase 1/2 Trial with INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

Posted on February 16, 2023

INOVIO to Report Fourth Quarter and Year-End 2022 Financial Results on March 1, 2023

Posted on February 15, 2023

INOVIO Reports Positive Phase 1b Results for INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®)

Posted on February 2, 2023

© Copyright 2025 INOVIO Pharmaceuticals. All rights reserved.